Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

DelveInsight’s report on the Moderate to Severe Plaque Psoriasis pipeline highlights a dynamic and evolving landscape, with ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...

GSK will pay $500 million to a Chinese firm for its experimental COPD drug; Why GLP-1s could become the "everything drug”; RFK Jr. plans to remove panel that makes preventative service recommendations ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...